Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. RTW Biotech Opportunities's selling, general, & admin. expense for the
six
months ended in Dec. 2025 was $2.5 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was $5.7 Mil.
RTW Biotech Opportunities (LSE:RTW) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
RTW Biotech Opportunities Selling, General, & Admin. Expense Related Terms
RTW Biotech Opportunities Selling, General, & Admin. Expense Historical Data
* Premium members only.
The historical data trend for RTW Biotech Opportunities's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities Selling, General, & Admin. Expense Chart
LSE:RTW vs BLK, BX, KKR: Selling, General, & Admin. Expense Comparison
For the Asset Management subindustry, RTW Biotech Opportunities's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities Selling, General, & Admin. Expense vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's Selling, General, & Admin. Expense falls into.
RTW Biotech Opportunities Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Selling, General, & Admin. Expense of $5.7 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Selling, General, & Admin. Expense of $5.7 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Selling, General, & Admin. Expense too high?
RTW Biotech Opportunities' current Selling, General, & Admin. Expense is $5.7 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Selling, General, & Admin. Expense compare to BLK and BX?
RTW Biotech Opportunities' Selling, General, & Admin. Expense of $5.7 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for an Asset Management company?
A good Selling, General, & Admin. Expense depends on the Asset Management industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Selling, General, & Admin. Expense is $5.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Selling, General, & Admin. Expense of $5.7 Mil. The current Selling, General, & Admin. Expense is $5.7 Mil. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Selling, General, & Admin. Expense is $5.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score
Get the complete analysis for LSE:RTW
Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
